Systemic therapy in bladder cancer

about

Identification of differentially expressed genes and biological pathways in bladder cancer.RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer

P2860

Q52658556-6B60EA43-0452-4291-BEA0-22581FCE2E4F Q54979788-402A5CD3-0722-439E-802C-DFA947C73DA2 Q58768900-13A35A1C-A309-4D85-9485-E3E6B7FD97E2

P2860

Systemic therapy in bladder cancer

Item

http://www.wikidata.org/entity/Q33578564

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Systemic therapy in bladder cancer

@ast

Systemic therapy in bladder cancer

@en

Systemic therapy in bladder cancer.

@nl

type

Item

label

Systemic therapy in bladder cancer

@ast

Systemic therapy in bladder cancer

@en

Systemic therapy in bladder cancer.

@nl

prefLabel

Systemic therapy in bladder cancer

@ast

Systemic therapy in bladder cancer

@en

Systemic therapy in bladder cancer.

@nl

P1476

Systemic therapy in bladder cancer

@en

P2093

Ian G Pinto

http://www.w3.org/2001/XMLSchema#string

P2860

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib.

Cancer statistics, 2015

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

Comprehensive molecular characterization of urothelial bladder carcinoma

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer.

Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration.

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration.

Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study.

P304

118-126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/IJU.IJU_294_16

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28469299

http://www.w3.org/2001/XMLSchema#string

P932

5396399

http://www.w3.org/2001/XMLSchema#string

Systemic therapy in bladder cancer

about

P2860

P2860

Systemic therapy in bladder cancer

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932